Search research articles
Contact Us
Filters
Showing results (91-100 of 138) with videos related to
Page
of 14
Sort By:
Journal of Managed Care Pharmacy : JMCP
|
April 29, 2008
HEDIS, beta-blockers, and what more can be done to improve secondary prevention in ACS
Frederic R Curtiss
Journal of Managed Care Pharmacy : JMCP
|
December 11, 2003
The relative value of disease management programs versus drug manufacturer rebates
Frederic R Curtiss
Journal of Managed Care Pharmacy : JMCP
|
November 23, 2005
Selectivity and specificity are the keys to cost-effective use of omalizumab for allergic asthma
Frederic R Curtiss
Journal of Managed Care Pharmacy : JMCP
|
April 21, 2006
Relative value of the NSAIDs, including COX-2 inhibitors and meloxicam
Frederic R Curtiss
Journal of Managed Care Pharmacy : JMCP
|
July 2, 2004
Methods to attain optimal outcomes with lipid-lowering drug therapy
Frederic R Curtiss
Journal of Managed Care Pharmacy : JMCP
|
December 11, 2003
Consensus panel, national guidelines, and other potentially misleading terms
Frederic R Curtiss
Journal of Managed Care Pharmacy : JMCP
|
March 16, 2005
Evidence-based medicine: United States, the last venue for direct-to-consumer advertising, props up the erectile dysfunction market
Frederic R Curtiss
Journal of Managed Care Pharmacy : JMCP
|
February 3, 2007
What evidence supports guidelines for use of ACE inhibitors and ARBs in diabetes?
Frederic R Curtiss
Journal of Managed Care Pharmacy : JMCP
|
March 31, 2009
Omalizumab and other new drug therapies occupy a small space in asthma disease management
Frederic R Curtiss
Journal of Managed Care Pharmacy : JMCP
|
July 4, 2007
Effective integration of medical and pharmacy claims to better protect patient safety--a long road yet to travel
Frederic R Curtiss
Page
of 14
Search research articles
Search
Showing results (91-100 of 138) with videos related to
Sort By:
Page
of 14
Journal of Managed Care Pharmacy : JMCP
|
April 29, 2008
HEDIS, beta-blockers, and what more can be done to improve secondary prevention in ACS
Frederic R Curtiss
Journal of Managed Care Pharmacy : JMCP
|
December 11, 2003
The relative value of disease management programs versus drug manufacturer rebates
Frederic R Curtiss
Journal of Managed Care Pharmacy : JMCP
|
November 23, 2005
Selectivity and specificity are the keys to cost-effective use of omalizumab for allergic asthma
Frederic R Curtiss
Journal of Managed Care Pharmacy : JMCP
|
April 21, 2006
Relative value of the NSAIDs, including COX-2 inhibitors and meloxicam
Frederic R Curtiss
Journal of Managed Care Pharmacy : JMCP
|
July 2, 2004
Methods to attain optimal outcomes with lipid-lowering drug therapy
Frederic R Curtiss
Journal of Managed Care Pharmacy : JMCP
|
December 11, 2003
Consensus panel, national guidelines, and other potentially misleading terms
Frederic R Curtiss
Journal of Managed Care Pharmacy : JMCP
|
March 16, 2005
Evidence-based medicine: United States, the last venue for direct-to-consumer advertising, props up the erectile dysfunction market
Frederic R Curtiss
Journal of Managed Care Pharmacy : JMCP
|
February 3, 2007
What evidence supports guidelines for use of ACE inhibitors and ARBs in diabetes?
Frederic R Curtiss
Journal of Managed Care Pharmacy : JMCP
|
March 31, 2009
Omalizumab and other new drug therapies occupy a small space in asthma disease management
Frederic R Curtiss
Journal of Managed Care Pharmacy : JMCP
|
July 4, 2007
Effective integration of medical and pharmacy claims to better protect patient safety--a long road yet to travel
Frederic R Curtiss
Page
of 14